Transposon Therapeutics
San Diego, US · Founded 2019 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
DP
Dennis PodlesakExecutive
LR
Lynne R. RollinsExecutive
EW
Eckard Weber, MDExecutive
EW
Eckard Weber, M.D.Executive
Board
DH
Daniel Hetu, MD, MBABoard director
BA
WH
William Harrington, MD, MBABoard director
JP
KA
Keith A. KatkinBoard director
BT
Brian Taylor Slingsby, MD, PHD, MPHBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$59.1M disclosed across 4 rounds · 2020–2024
▶$4.7MraisedJul 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$4.7MraisedJul 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith A. KatkinDirector
- Dennis PodlesakExecutive Officer, Director
- Lynne R. RollinsExecutive Officer
- Daniel Hetu, MD, MBADirector
- Eckard Weber, MDExecutive Officer, Director
- Brent AhrensDirector
- Brian Taylor Slingsby, MD, PHD, MPHDirector
- William Harrington, MD, MBADirector
- John PacificoDirector
- Offering amount
- $20M
- Amount sold
- $4.7M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedJan 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJan 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Lynne R. RollinsExecutive Officer
- William Harrington, MD, MBADirector
- Brent AhrensDirector
- Daniel Hetu, MD, MBADirector
- Eckard Weber, MDExecutive Officer, Director
- Keith A. KatkinDirector
- Brian Taylor Slingsby, MD, PHD, MPHDirector
- John PacificoDirector
- Offering amount
- $20M
- Amount sold
- $5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$45.2MraisedDec 2020 · 10 investors · PharmaceuticalsRule 506(b)
▶$45.2MraisedDec 2020 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakExecutive Officer, Director
- Eckard Weber, M.D.Executive Officer, Director
- John PacificoDirector
- Brent AhrensDirector
- Lynne R. RollinsExecutive Officer
- Offering amount
- $45.2M
- Amount sold
- $45.2M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.3MraisedMay 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedMay 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Eckard Weber, M.D.Executive Officer, Director
- Brent AhrensDirector
- John PacificoDirector
- Lynne RollinsExecutive Officer
- Offering amount
- $6.5M
- Amount sold
- $4.3M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Contract7 shared keywordsContract Pharma is a trade media publication covering the pharmaceutical and biopharmaceutical industry, with a focus on contract development and manufacturing (CDMO) topics. It provides industry news, magazine issues, expert interviews, webinars, whitepapers, company directories, and event coverage for professionals in the pharma and biopharma sector.
Companies competing with Transposon Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who are Transposon Therapeutics's investors?
- Transposon Therapeutics's investors include Canaan Partners.
- How much funding has Transposon Therapeutics raised?
- Transposon Therapeutics has disclosed $59.1M raised across 4 rounds.
- Where is Transposon Therapeutics headquartered?
- Transposon Therapeutics is headquartered in San Diego, US.